Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Debt / NOTE 2.250% 2/0
-
Market price (% of par)
-
47.62%
-
Total 13F principal
-
$625,412,958
-
Principal change
-
+$623,286,958
-
Total reported market value
-
$310,645,005
-
Number of holders
-
36
-
Value change
-
+$309,619,000
-
Number of buys
-
35
Institutional Holders of BRIDGEBIO PHARMA INC - NOTE 2.250% 2/0 as of Q1 2022
As of 31 Mar 2022,
BRIDGEBIO PHARMA INC - NOTE 2.250% 2/0 was held by
36 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$625,412,958
in principal (par value) of the bond.
The largest 10 bondholders included
Allianz Asset Management GmbH, Diameter Capital Partners LP, AMERIPRISE FINANCIAL INC, INHERENT GROUP, LP, DeepCurrents Investment Group LLC, Aequim Alternative Investments LP, ARISTEIA CAPITAL LLC, ORBIMED ADVISORS LLC, AVIVA PLC, and Antara Capital LP.
This page lists
36
institutional bondholders reporting positions
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.